We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why
Read MoreHide Full Article
Recursion Pharmaceuticals (RXRX - Free Report) ended the recent trading session at $4.98, demonstrating a +1.32% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.44%. At the same time, the Dow added 0.14%, and the tech-heavy Nasdaq gained 0.7%.
Shares of the biotechnology company have depreciated by 0.61% over the course of the past month, underperforming the Medical sector's gain of 1.25%, and the S&P 500's gain of 4.03%.
Market participants will be closely following the financial results of Recursion Pharmaceuticals in its upcoming release. The company is expected to report EPS of -$0.35, down 2.94% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $17.45 million, indicating a 33.11% downward movement from the same quarter last year.
RXRX's full-year Zacks Consensus Estimates are calling for earnings of -$1.48 per share and revenue of $72.38 million. These results would represent year-over-year changes of +12.43% and +23.02%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Recursion Pharmaceuticals. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Recursion Pharmaceuticals is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 101, finds itself in the top 41% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why
Recursion Pharmaceuticals (RXRX - Free Report) ended the recent trading session at $4.98, demonstrating a +1.32% change from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.44%. At the same time, the Dow added 0.14%, and the tech-heavy Nasdaq gained 0.7%.
Shares of the biotechnology company have depreciated by 0.61% over the course of the past month, underperforming the Medical sector's gain of 1.25%, and the S&P 500's gain of 4.03%.
Market participants will be closely following the financial results of Recursion Pharmaceuticals in its upcoming release. The company is expected to report EPS of -$0.35, down 2.94% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $17.45 million, indicating a 33.11% downward movement from the same quarter last year.
RXRX's full-year Zacks Consensus Estimates are calling for earnings of -$1.48 per share and revenue of $72.38 million. These results would represent year-over-year changes of +12.43% and +23.02%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Recursion Pharmaceuticals. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Recursion Pharmaceuticals is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 101, finds itself in the top 41% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.